skip banner navigation
National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Late Effects of Childhood Cancer Therapies (PDQ®)
Health Professional VersionEn EspañolLast Modified: 07/22/2004




General Information






Common Late Effects of Childhood Cancer by Body System






Second Malignant Neoplasms






Mortality






Monitoring for Late Effects






Changes to This Summary (07/22/04)






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Dictionary

Funding Opportunities

NCI Publications

NCI Calendar

Español
NCI Highlights
October is Breast Cancer Awareness Month

NCI Annual Progress Report on Cancer Research 2003

Women, Tobacco and Cancer: Agenda for 21st Century

Past Highlights
Need Help?
General Information

During the past 3 decades, multimodality therapy for childhood cancer has resulted in markedly improved survival. For the period 1985-1997, the 5-year survival rate for childhood cancer reported by the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program is 75%.[1] The therapy responsible for this survival can also produce adverse long-term health-related outcomes that manifest months to years after completion of cancer treatment, and are commonly referred to as “late effects.” Late effects include organ dysfunction, second malignant neoplasms, and adverse psychosocial sequelae.

Risk factors for late effects include:

  • Tumor-related factors
    • Direct tissue effects
    • Tumor-induced organ dysfunction
    • Mechanical effects


  • Treatment-related factors
    • Radiation therapy: Total dose and fraction size, organ or tissue volume, and machine energy are the most critical factors
    • Chemotherapy: Agent type, single and cumulative dose and schedule may modify risk
    • Surgery: Technique and site are relevant


  • Host-related factors
    • Developmental status
    • Genetic predisposition
    • Inherent tissue sensitivities and capacity for normal tissue repair
    • Function of organs not affected by radiotherapy or chemotherapy
    • Premorbid state


Several comprehensive reviews and books that address late effects of childhood cancer and its therapy have been published.[2-8] This summary will discuss some of these late effects in detail by organ system and will address issues of second malignant neoplasms, mortality, and monitoring.

Common Agents Associated With Late Therapy Effects
Agent/Agent Class/Modality  Affected Body System 
AnthracyclinesCirculatory (Cardiac)
Respiratory (Pulmonary)
Alkylating agentsReproductive (Gonadal)
Second malignant neoplasms
Topoisomerase II inhibitorsSecond malignant neoplasms
PlatinumsUrinary (Renal)
Special Senses (Hearing)
Second malignant neoplasms
CorticosteroidsCentral nervous system
Musculoskeletal (Bone and body composition)
Musculoskeletal (Obesity)
Intrathecal chemotherapyCentral nervous system
BleomycinRespiratory (Pulmonary)
MethotrexateCentral nervous system
VincristineDigestive (Dental)
ThioguanineDigestive (Hepatic)

Information concerning late effects is summarized in Tables throughout the summary. Tables in the Common Late Effects of Childhood Cancer by Body System section of the summary have been modified from other reviews, with author permission.[5]

References

  1. Ries LA, Smith MA, Gurney JG, et al., eds.: Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda, Md: National Cancer Institute, SEER Program, 1999. NIH Pub.No. 99-4649. Also available online. Last accessed March 5, 2004. 

  2. Marina N: Long-term survivors of childhood cancer. The medical consequences of cure. Pediatr Clin North Am 44 (4): 1021-42, 1997.  [PUBMED Abstract]

  3. Meister LA, Meadows AT: Late effects of childhood cancer therapy. Curr Probl Pediatr 23 (3): 102-31, 1993.  [PUBMED Abstract]

  4. Schwartz CL: Long-term survivors of childhood cancer: the late effects of therapy. Oncologist 4 (1): 45-54, 1999.  [PUBMED Abstract]

  5. Schwartz C L, Hobbie WL, Constine LS, et al., eds.: Survivors of Childhood Cancer: Assessment and Management. St. Louis, Mo: Mosby, 1994. 

  6. Constine LS: Late effects of cancer treatment. In: Halperin EC, Constine LS, Tarbell NJ, et al.: Pediatric Radiation Oncology. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 1999, pp 457-537. 

  7. Green DM, D'Angio GJ, eds.: Late Effects of Treatment for Childhood Cancer. New York, NY: Wiley-Liss, Inc., 1992. 

  8. Friedman DL, Meadows AT: Late effects of childhood cancer therapy. Pediatr Clin North Am 49 (5): 1083-106, x, 2002.  [PUBMED Abstract]

Back to TopBack to Top

Next Section >

skip footer navigation

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health FirstGov.gov